Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT06233331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal intraepithelial neoplasia, high-grade squamous intraepithelial lesions, human immunodeficiency virus, human papilloma virus